Cancer & Immunotherapy: greatest challenges and novel therapies inspiring European citizens
20 March - 2:30 am - 6:30 pm CET
HOPE is joining the organisation of the FEAM European Biomedical Policy Forum next annual lecture 2020 on ‘Cancer & Immunotherapy: greatest challenges and novel therapies inspiring European citizens’, also supported by Cancer Research UK).
On July 2019, the Commissioner for Research, Science and Innovation – Carlos Moedas -officially launched the work on five major European research and innovation missions that will be part of Horizon Europe. These new European R&I missions aim to deliver solutions to some of the greatest challenges facing our world, including cancer. In addition, DG SANTE is producing proposals for Europe’s Beating Cancer Plan, the Commission’s policy agenda to improve cancer control and care.
Cancer is a complex disease in which cells in a specific tissue are no longer fully responsive to the signals within the tissue that regulate cellular differentiation, survival, proliferation and death. As result, these cells accumulate and invade other tissues, causing local damages and inflammation. There are over 200 different types of cancer. In this context, the immuno-oncology is a type of cancer treatment that uses the power of the body’s own immune system to prevent, control, and eliminate cancer. Also known as immunotherapy, this innovative treatment comes in a variety of forms, including targeted antibodies, cancer vaccines, adoptive cell transfer, tumor-infecting viruses, checkpoint inhibitors, cytokines, and adjuvants. Some immunotherapy treatments also use genetic engineering to enhance immune cells’ cancer-fighting capabilities (CAR-T cells).
With a unique European focus on cancer research and treatment emerging, the aim of this annual lecture is how we can harness this radical treatment to better manage and eradicate cancer. The event will consist in an interactive debate – with high-profile list of speakers – discussing progress and new frontiers in immunotherapy research, and how we might translate this work into tangible outcomes for patients.
In particular, the discussion will focus on how policymakers can help support the uptake of immunotherapy treatments, reduce barriers to access, and encourage further research into this most promising field. This is an initiative to unite research experts, European authorities, patient groups and stakeholder communities working in this field.